author-photo

Joanne L. Blum

Texas Oncology
Baylor University Medical Center
Baylor University

157

Papers

8805

Citations

Citation Trend

Filter By

Papers (157) Sort By

Journal Conference Others

Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from POLARIS.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Impact of COVID-19 on study sites: Survey analysis from the noninterventional POLARIS study

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS7-19: Pre/perimenopausal (preMeno) women receiving palbociclib (PAL) for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC) in a real-world setting: Treatment patterns from POLARIS

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract SS2-10: Impact of COVID-19 on study sites: Survey analysis from the noninterventional POLARIS study

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
106P Palbociclib (PAL) in male patients (pts) with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC): Pt characteristics and treatment (Tx) patterns from the POLARIS study

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract LB033: Longitudinal ctDNA changes in patients with long-term response to palbociclib combination therapy for advanced breast cancer: A preliminary analysis from the real-world POLARIS study

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician’s choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)